Qyuns Therapeutics Co., Ltd. Class H (HK:2509)
:2509
Want to see HK:2509 full AI Analyst Report?
Total Valuation
Qyuns Therapeutics Co., Ltd. Class H has a market cap or net worth of HK$3.91B. The enterprise value is HK$2.99B.
Market CapHK$3.91B
Enterprise ValueHK$2.99B
Share Statistics
Qyuns Therapeutics Co., Ltd. Class H has 227,071,600 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding227,071,600
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Qyuns Therapeutics Co., Ltd. Class H’s return on equity (ROE) is 0.44 and return on invested capital (ROIC) is 25.02%.
Return on Equity (ROE)0.44
Return on Assets (ROA)0.19
Return on Invested Capital (ROIC)25.02%
Return on Capital Employed (ROCE)0.29
Revenue Per Employee2.32M
Profits Per Employee906.70K
Employee Count339
Asset Turnover0.49
Inventory Turnover3.19
Valuation Ratios
The current PE Ratio of Qyuns Therapeutics Co., Ltd. Class H is 12.3. Qyuns Therapeutics Co., Ltd. Class H’s PEG ratio is -0.06.
PE Ratio12.3
PS Ratio4.80
PB Ratio5.43
Price to Fair Value5.43
Price to FCF9.62
Price to Operating Cash Flow-21.97
PEG Ratio-0.06
Income Statement
In the last 12 months, Qyuns Therapeutics Co., Ltd. Class H had revenue of 786.08M and earned 306.31M in profits. Earnings per share was 1.37.
Revenue786.08M
Gross Profit664.66M
Operating Income319.74M
Pretax Income299.42M
Net Income306.31M
EBITDA351.00M
Earnings Per Share (EPS)1.37
Cash Flow
In the last 12 months, operating cash flow was -211.00M and capital expenditures -2.38M, giving a free cash flow of -213.39M billion.
Operating Cash Flow-211.00M
Free Cash Flow-213.39M
Free Cash Flow per Share-0.94
Dividends & Yields
Qyuns Therapeutics Co., Ltd. Class H pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.60
52-Week Price Change52.21%
50-Day Moving Average19.06
200-Day Moving Average21.73
Relative Strength Index (RSI)55.57
Average Volume (3m)305.01K
Important Dates
Qyuns Therapeutics Co., Ltd. Class H upcoming earnings date is Aug 14, 2026, Before Open (Confirmed).
Last Earnings DateMar 27, 2026
Next Earnings DateAug 14, 2026
Ex-Dividend Date―
Financial Position
Qyuns Therapeutics Co., Ltd. Class H as a current ratio of 2.22, with Debt / Equity ratio of 280.94%
Current Ratio2.22
Quick Ratio2.14
Debt to Market Cap0.15
Net Debt to EBITDA-1.09
Interest Coverage Ratio14.81
Taxes
In the past 12 months, Qyuns Therapeutics Co., Ltd. Class H has paid 71.11K in taxes.
Income Tax71.11K
Effective Tax Rate<0.01
Enterprise Valuation
Qyuns Therapeutics Co., Ltd. Class H EV to EBITDA ratio is 9.66, with an EV/FCF ratio of 8.65.
EV to Sales4.31
EV to EBITDA9.66
EV to Free Cash Flow8.65
EV to Operating Cash Flow8.48
Balance Sheet
Qyuns Therapeutics Co., Ltd. Class H has HK$558.90M in cash and marketable securities with HK$635.93M in debt, giving a net cash position of -HK$77.04M billion.
Cash & Marketable SecuritiesHK$558.90M
Total DebtHK$635.93M
Net Cash-HK$77.04M
Net Cash Per Share-HK$0.34
Tangible Book Value Per ShareHK$2.94
Margins
Gross margin is 77.76%, with operating margin of 40.68%, and net profit margin of 38.97%.
Gross Margin77.76%
Operating Margin40.68%
Pretax Margin38.09%
Net Profit Margin38.97%
EBITDA Margin44.65%
EBIT Margin40.68%
Analyst Forecast
The average price target for Qyuns Therapeutics Co., Ltd. Class H is HK$33.50, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price TargetHK$33.50
Price Target Upside17.21% Upside
Analyst ConsensusStrong Buy
Analyst Count3
Revenue Growth Forecast410.53%
EPS Growth Forecast―